Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
Alterity Therapeutics announced positive regulatory feedback from a Type C Meeting with the FDA regarding its planned Phase 3 clinical trial program for ATH434 targeting Multiple System Atrophy (MSA). The FDA has provided written support for clinical pharmacology and non-clinical development plans, marking a significant step toward initiating the P…